^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aybintio (bevacizumab biosimilar)

    i
    Company:
    3SBio, Mundipharma, Samsung
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Apply
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (ECOG-ACRIN EA3202) (NCT05063552)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2023
    Primary completion :
    12/15/2027
    Completion :
    12/15/2027
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01950390)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/24/2014
    Primary completion :
    10/06/2021
    Completion :
    01/31/2026
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (ECOG-ACRIN 5103) (NCT00433511)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/02/2007
    Primary completion :
    01/07/2014
    Completion :
    02/22/2025
    HER-2 • ER
    |
    Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • cyclophosphamide intravenous
    Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (A092001) (NCT05001880)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/22/2022
    Primary completion :
    08/20/2025
    Completion :
    08/20/2025
    MSLN
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Pemfexy (pemetrexed)
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (NCT05211323)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    12/07/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    IL2
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (CALGB-40503) (NCT00601900)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/24/2008
    Primary completion :
    06/30/2014
    Completion :
    05/30/2025
    ER • PGR
    |
    ER expression
    |
    Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)
    Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (CALGB 40603) (NCT00861705)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/15/2009
    Primary completion :
    08/01/2014
    Completion :
    02/22/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • cyclophosphamide intravenous
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (NCT01081262)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/12/2010
    Primary completion :
    02/25/2015
    Completion :
    03/01/2025
    KRAS
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • capecitabine • oxaliplatin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (NCT06696768)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    01/16/2025
    Initiation :
    02/28/2025
    Primary completion :
    10/31/2025
    Completion :
    10/31/2025
    IFNG • IL6 • CCL2 • CXCL1 • IRAK4
    |
    Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical
    Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (NRG-GY036) (NCT06580314)
    Phase 3
    NRG Oncology
    Not yet recruiting
    Last update posted :
    08/30/2024
    Initiation :
    01/16/2025
    Primary completion :
    12/31/2034
    Completion :
    12/31/2035
    BRCA
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Aybintio (bevacizumab biosimilar) • Avzivi (bevacizumab-tnjn)
    A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK) (NCT05904457)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    06/14/2023
    Initiation :
    01/02/2023
    Primary completion :
    01/31/2025
    Completion :
    01/31/2026
    FH
    |
    Avastin (bevacizumab) • erlotinib • Aybintio (bevacizumab biosimilar)